Please wait while the formulary information is being retrieved.
PAINGO KFT (LIDOCAINE/PRILOCAINE/METHYL SALICYLATE/MENTHOL)
2.5 %-2.5 %-30 %-10 % topical cream
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Large open wound
- Methemoglobinemia
Contraindicated
- Burns
- Cardiac arrhythmia
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart block
- Hemolytic anemia from PK and g6PD deficiencies
- Sepsis
- Shock
Severe
Moderate
- Disease of liver
- Respiratory depression
- Seizure disorder
PAINGO KFT (LIDOCAINE/PRILOCAINE/METHYL SALICYLATE/MENTHOL)
- None
- Stinging of skin
More Frequent
Severe
Less Severe
- Angioedema
- Dermatitis due to topical drug
- Erythema
- Pruritus of skin
- Skin rash
- Stinging of skin
- Urticaria
- Dry skin
- Skin irritation
- Stinging of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Anaphylaxis
- Bradycardia
- Burns
- Cardiac arrhythmia
- CNS toxicity
- Cyanosis
- Drowsy
- Dyspnea
- Eyelid edema
- Facial edema
- Headache disorder
- Hypersensitivity drug reaction
- Hypotension
- Methemoglobinemia
- Periorbital edema
- Pharyngeal edema
- Respiratory depression
- Seizure disorder
- Skin ulcer
- Superficial skin ulcer
- Syncope
- Throat constriction
- Tremor
- Unconsciousness
- Urticaria
Less Severe
- Acute confusion
- Apprehension
- Blurred vision
- Dizziness
- Edema
- Euphoria
- Nervousness
- Pruritus of skin
- Sensation of cold
- Sensation of warmth
- Tinnitus
- Twitching
- Vomiting
Contraindicated
None
Severe Precaution
Lidocaine (Top)
Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
Rare risk of methemoglobinemia in infants age < 6 months. Adhere closely to dosing guidelines age < 10 years.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
Prilocaine
Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
Rare risk of methemoglobinemia in infants age < 6 months. Adhere closely to dosing guidelines age < 10 years.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Adhere closely to dosing guidelines age < 10 years.
Management or Monitoring Precaution
Lidocaine (Top)
Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 180 Days – 13 Years
- Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
- 180 Days – 10 Years
- Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
- 1 Day – 13 Years
- Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Prilocaine
Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 180 Days – 13 Years
- Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
- 180 Days – 10 Years
- Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
- 1 Day – 13 Years
- Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
Salicylates (Topical)
Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Rare risk of methemoglobinemia. Adhere closely to dosing guidelines age < 10 years.
Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 180 Days – 13 Years
- Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 180 Days – 10 Years
- Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
- 1 Day – 13 Years
- Prolonged use or use on extensive skin areas may lead to systemic toxicity, e.g. hemostatic or metabolic changes.
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Prilocaine Hydrochloride
- Severity Level:
2
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Methyl Salicylate (topical/nasal)
Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates |
Prilocaine
Small amt of drug absorbed systemically;Risk of reye's syn w/oral salicylates
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
Select Anesthetics
General-May be more sensitive to CNS and cardiac adverse reactions. Consider dose reduction due to reduced clearance in the elderly.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Formulary Reference Tool